Upstream Bio annual return on equity
2024
2025
Upstream Bio Return on Equity (ROE) Growth & History (UPB)
Upstream Bio's return on equity was −35.43% for fiscal 2025.
View full Upstream Bio company overviewUpstream Bio annual return on equity history
| Fiscal year | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −35.43% | +0.79 pp |
| 2024 | 2024-12-31 | −36.23% | — |
Upstream Bio quarterly return on equity
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | −13.81% | −4.45 pp |
| Q1 2026 | 2026-03-31 | −12.61% | −6.65 pp |
| Q4 2025 | 2025-12-31 | −11.82% | +1.90 pp |
| Q3 2025 | 2025-09-30 | −8.57% | — |
| Q2 2025 | 2025-06-30 | −9.36% | — |
| Q1 2025 | 2025-03-31 | −5.96% | — |
| Q4 2024 | 2024-12-31 | −13.72% | — |
Upstream Bio return on equity trends
Between the periods ended 2024-12-31 and 2025-12-31, Upstream Bio's return on equity increased from −36.23% to −35.43%, a change of +0.79 percentage points. The latest reported quarter, Q2 2026, shows −13.81%.
About the metric
What return on equity (ROE) means
Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.
Calculation and source
How return on equity is calculated
TickerStat calculates ROE as SEC-reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Upstream Bio source filings ↗